Real-Time Polymerase Chain Reaction of Immunoglobulin Rearrangements for Quantitative Evaluation of Minimal Residual Disease in Multiple Myeloma

Biology of Blood and Marrow Transplantation

Volumn 6, Issue 3, 2000, Pages 241-253

  Ladetto, Marco ^a   Donovan, John W ^a   Harig, Sabine ^a   Weller, Edie ^a   Trojan, Andreas ^a   Poor, Christina ^a   Schlossman, Robert ^a   Anderson, Kenneth C ^a   Gribben, John G ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Consensus probe; IgH rearrangement; PCR; Tumor burden

Indexed keywords

ARTICLE; AUTOTRANSPLANTATION; GENE REARRANGEMENT; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOGLOBULIN GENE; IMMUNOLOGY; METHODOLOGY; MINIMAL RESIDUAL DISEASE; MULTIPLE MYELOMA; PATHOLOGY; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

GENE REARRANGEMENT, B-LYMPHOCYTE, HEAVY CHAIN; GENES, IMMUNOGLOBULIN; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MULTIPLE MYELOMA; NEOPLASM, RESIDUAL; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TRANSPLANTATION, AUTOLOGOUS;

EID: 0033642606     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1083-8791(00)70006-1     Document Type: Article

References (46)

1. Harousseau JL, Milipied N, Laporte JP, et al. Double-intensive therapy in high-risk multiple myeloma. Blood. 1992;79:2827-2833.
2. Anderson KC, Anderson J, Soiffer R, et al. Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma. Blood. 1993;82:2568-2576.
3. Gianni AM, Tarella C, Bregni M, et al. High-dose sequential chemoradiotherapy, a widely applicable regimen, confers survival benefit to patients with high-risk multiple myeloma. J Clin Oncol. 1994;12:503-509.
4. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma: Intergroupe Francais du Myelome. N Engl J Med. 1996;335:91-97.
5. Barlogie B, Jagannath S, Desikan KR, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood. 1999;93:55-65.
6. Corradini P, Voena C, Astolfi M, et al. High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting. Blood. 1995;85:1596-1602.
7. + peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma. Blood. 1995;86:390-397.
8. Lemoli RM, Cavo M, Fortuna A. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma. J Hematother. 1996;5:339-349.
9. Corradini P, Voena C, Tarella T, et al. Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transpantation of hematopoietic cell. J Clin Oncol. 1999;17:208-215.
10. Bird JM, Russell NH, Samson D. Minimal residual disease after bone marrow transplantation for multiple myeloma: evidence for cure in long-term survivors. Bone Marrow Transplant. 1993; 12:651-654.
11. Vescio R, Schiller G, Stewart AK, et al. Multicenter phase III trial to evaluate CD34(+) selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma. Blood. 1999;93:1858-1868.
12. Brisco MJ, Condon J, Hughes E, et al. Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction. Lancet. 1994; 343:196-200.
13. Steenbergen EJ, Verhagen OJ, van Leeuwen EF, et al. IgH/TCR delta PCR oligonucleotide liquid hybridization, a fast and sensitive assay for monitoring minimal residual disease in childhood B-precursor ALL. Leukemia. 1995;9:216-222.
14. Provan D, Zwicky C, Bartlett-Pandite L, et al. Eradication of PCR detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood. 1996;88:2228-2235.
15. Andersen NS, Donovan JW, Bonis JS, et al. Failure of immunologic purging in mantle cell lymphoma assessed by PCR detection of minimal residual disease. Blood. 1997;90:4212-4221.
16. Corradini P, Astolfi M, Cherasco C, et al. Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkins lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting. Blood. 1997;89:724-731.
17. Billadeau D, Blackstadt M, Greipp P, et al. Analysis of B-lymphoid malignancies using allele-specific polymerase chain reaction: a technique for sequential quantitation of residual disease. Blood. 1991;78:3021-3029.
18. Billadeau D, Quam L, Thomas W, et al. Detection and quantitation of malignant cells in the peripheral blood of multiple myeloma patients. Blood. 1992;80:1818-1824.
19. Gazitt Y, Reading CC, Hoffman R, et al. Purified CD34(+) Lin(-) Thy(+) stem cells do not contain clonal myeloma cells. Blood. 1995;86:381-389.
20. Vescio RA, Han EJ, Schiller GJ, et al. Quantitative comparison of multiple myeloma tumor contamination in bone marrow harvest and leukapheresis autografts. Bone Marrow Transplant. 1996; 18:103-110.
21. Chen BJ, Epstein J. Circulating clonal lymphocytes in myeloma constitute a minor subpopulation of B cells. Blood. 1996;87: 1972-1976.
22. Cremer FW, Kiel K, Wallmeier M, Goldschmidt H, Moos M. A quantitative PCR assay for the detection of malignant cells in multiple myeloma. Ann Oncol. 1997;8:633-636.
23. Cremer FW, Kiel K, Wallmeier M, Haas R, Goldschmidt H, Moos M. Leukapheresis products in multiple myeloma: lower tumor load after mobilization with cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) compared with G-CSF alone. Exp Hematol. 1998;26:969-975.
24. Kay NE, Leong T, Kyle RA, et al. Circulating blood B cells in multiple myeloma: analysis and relationship to circulating clonal cells and clinical parameters in a cohort of patients entered on the Eastern Cooperative Oncology Group phase III E9486 clinical trial. Blood. 1997;90:340-345.
25. Gibson UEM, Heid CA, Williams PM. A novel method for real time quantitative RT-PCR. Genome Res. 1996;6:995-1001.
26. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res. 1996;6:986-994.
27. Orlando C, Pinzani P, Pazzagli M. Developments in quantitative PCR [renew]. Clin Chem Lab Med. 1998;36:255-269.
28. Holland PM, Abramson RD, Watson R, Gelfand DH. Detection of specific polymerase chain reaction product by utilizing the 5′→3′ exonuclease activity of Thermus aquaticus DNA polymerase. Proc Natl Acad Sci U S A. 1991;88:7276-7280.
29. Lee LG, Connell CR, Bloch W. Allelic discrimination by nick-translation PCR with fluorogenic probes. Nucleic Acids Res. 1993;21:3761-3766.
30. Gerard CJ, Arboleda MJ, Solar G, Mule JJ, Kerr WG. A rapid and quantitative assay to estimate gene transfer into retrovirally transduced hematopoietic stem/progenitor cells using a 96-well format PCR and fluorescent detection system universal for MMLV-based provinces. Hum Gene Ther. 1996;10:343-354.
31. Luthra R, McBride JA, Cabanillas F, Sarris A. Novel 5′ exonuclease-based real-time PCR assay for the detection of t(14;18) (q32;q21) in patients with follicular lymphoma. Am J Pathol. 1998;153:63-68.
32. Mensink E, van de Locht A, Scattenberg A, et al. Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real-time quantitative RT-PCR. Br J Haematol. 1998;102:768-774.
33. Marcucci G, Livak KJ, Bi W, Strout MP, Bloomfield CD, Caligiuri M. Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay. Leukemia. 1998;12:1482-1489.
34. Gerard CJ, Olsson K, Ramanathan R, Reading C, Hanania EG. Improved quantitation of minimal residual disease in multiple myeloma using real-time polymerase chain reaction and plasmid-DNA complementarity determining region III standards. Cancer Res. 1998;58:3957-3964.
35. Pongers-Willemse MJ, Verhagen OJ, Tibbe GJ, et al. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes. Leukemia. 1998;12:2006-2014.
36. Sahota SS, Leo R, Hamblin TJ, Stevenson FK. IgVH gene mutational patterns indicate different tumor cell status in human myeloma and monoclonal gammopathy of undetermined significance. Blood. 1996;87:746-755.
37. Higuchi R. Simple and rapid preparation of samples for PCR. In: Erlich HA, ed. PCR Technology. New York, NY: Stockton Press; 1989:31-38.
38. Voena C, Ladetto M, Astolfi M, et al. A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors. Leukemia. 1997;11:1793-1798.
39. Donovan JW, Ladetto M, Zou G, et al. Immunoglobulin heavy chain consensus probes for real-time PCR quantification of residual disease in acute lymphoblastic leukemia. Blood. 2000; 95:2651-2658.
40. Deane M, Baker BW, Norton JD. Immunoglobulin VH4 gene usage in B lymphoid leukaemias. Br J Haematol. 1993;84:242-249.
41. H4-34) gene. Blood. 1996;87:2846-2852.
42. Ercolani L, Florence B, Denaro M, Alexander M. Isolation and complete sequence of a functional human glyceraldehyde-3-phosphate dehydrogenase gene. J Biol Chem. 1988;263:15,335-15,341.
43. Woolson R. Statistical Methods for the Analysis of Biomedical Data. New York, NT: John Wiley & Sons; 1987.
44. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159-174.
45. Palumbo A, Battaglio S, Napoli P, et al. Recombinant interferon-gamma inhibits the in vitro proliferation of human myeloma cells. Br J Haematol. 1994;86:726-732.
46. Saily M, Koistinen P, Laine S, Soppi E, Savolainen ER. Hematopoietic growth factors stimulate paraprotein isotype production by bone marrow mononuclear cells in an aggressive case of multiple myeloma. J Clin Lab Immunol. 1995;46:41-47.